Magellan Health Inc., which has created Click Therapeutics and Digital Therapeutic solutions, today announced a digital, integrated and comprehensive smoking cessation program.
The pharmacy benefit management (PBM) in combination with Click’s technology and machine learning will serve to perpetuate this endeavor. The full program, including access to a real-time data analytics portal, will be available to Magellan’s employer, managed care and government customers.
CLICKOTINE is a comprehensive smoking cessation platform that works in tandem with Magellan’s resources, including access to live coaching, a clinical call center and PBM resources to provide quit aids, including nicotine replacement therapy.
By using this platform, people can have more tools to effectively take control of their health and overcome nicotine addiction.
Dr. Seth Feuerstein, chief medical officer of medical and digital innovation at Magellan Health, will join Click Therapeutics’ board of directors.
Feuerstein is a member of the Advisory Board at the Center for Biomedical and Interventional Technology at Yale University, as well as a member of the Yale University School of Medicine clinical faculty.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Photo: Flickr user Qfamily
